Abstract:

Polycystic Ovary Syndrome (PCOS) is a complex and multifactorial condition, involving a combination of genetic, hormonal, and environmental factors, and its etiology is unknown. PCOS poses a diagnostic challenge in adolescents, and assessing the status of biomarkers in adolescents and middle-aged women will elucidate the aetiology of PCOS. To evaluate the clinical biomarkers - SHBG, testosterone, AMH, insulin, and leptin - in both adolescence and middle-aged groups. This cross-sectional study was conducted at Sree Balaji Medical College and Hospital and involved a total of 200 subjects. The participants were divided into two groups, each having two subgroups. Adolescent females with regular periods made up Group 1(a), whereas those with irregular cycles and ages ranging from 18 to 19 made up Group 1(b). Middle-aged women with PCOS made up Group 2(a), whereas control subjects between the ages of 30 and 38 made up Group 2(b). The data were presented in the form of mean ± SD. To assess the variance in the data among multiple groups, a one-way analysis of variance (ANOVA) was employed to identify the least significant difference during group-wise comparisons. Statistical Package for the Social Sciences (SPSS) was used for all statistical analyses, with a significance threshold of P<0.05. The values of SHBG and AMH were significantly different between the four groups, and the value of insulin was significant between controls and oligomenorrhea in the adolescent group. This study reveals the sequential expression of physiological and clinical biochemical variations, suggesting that compensatory hyperinsulinemia may play a role in initiating PCOS pathogenesis.

References:

[1].   Azziz, R., Carmina, E., Chen, Z., Dunaif, A., Laven, J.S., Legro, R.S., Lizneva, D., Natterson-Horowtiz,B.,Teede,H.J.,Yildiz,B.O.,2016, Polycysticovary syndrome. Nature reviews Disease primers, 2(1), 1-18.

[2].    Bharali, M.D., Radhika R., Jayshree G., Kusum S., and Vinoth R., 2022,Prevalence of Polycystic Ovarian Syndrome in India: A Systematic Review and Meta-Analysis. Cureus,  14(12): e32351.

[3].    Pena, A.S., Witchel, S.F.,  Hoeger, K.M.,  Oberfield, S.E.,  Vogiatzi, M.G, Misso, M., Garad, R., Dabadghao Preeti., and Teede H., 2020, Adolescent polycystic ovary syndrome according to the international evidence- based guideline. BMC Med,  18, 72.

[4].    Sirmans, S.M and Pate, K.A., 2014, Epidemiology, diagnosis, and management of polycystic ovary syndrome. Clin Epidemiol, 6, 1–13.

[5].   Bulsara J., Patel P., Soni A., Acharya A., 2021, A review: brief insight into polycystic  ovarian syndrome. Endocr Metab Sci, 3,100085. 

[6].   Capozzi, G., Scambia, S., Lello., 2020, Polycystic ovary syndrome (PCOS) and adolescence: How can we manage it? European Journal of Obstetrics & Gynecology and Reproductive Biology, 250, 235-240.

[7].   Patel, S., 2018, Polycystic ovary syndrome (PCOS), an inflammatory, systemic, lifestyle endocrinopathy.The Journal of Steroid Biochemistry and Molecular Biology,182, 27-36.

[8].   Pappalardo, M.A., Russo G.T., Pedone, A., Pizzo, A., Borrielli, I., Stabile, G., Artenisio, A.C., Amato, Ucinotta, D. et al., 2010,Very high frequency of the polymorphism for the insulin receptor substrate 1 (IRS-1) at codon 972 ( glycine 972 Arginine) in southern Italian women with polycystic syndrome. Horm.Metab.Res, 42, 575-584.

[9].   Kandarakis, D.E. and Dunaif, A., 2012, Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocrine reviews,33 (6),981-1030.

[10].  RaymondLi, H.W.,  Yeung, W.S.B., Chung Ho, P., Hung, E.Y. N., 2011, Evaluation of serum antimullerian hormone and inhibin B concentrations in the differential diagnosis of secondary oligoamenorrhea.Fertil Steril, 96, 774-779.

[11].  Aghadavod, E., Zarghami, N., Farzadi, L., 2015,Evaluation of relationship between serum levels of anti-mullerian hormone, androgen, and insulin resistant with retrieval Oocytes in overweight patients with polycystic ovary syndrome. Adv Biomed Res, 4, 76.

[12].  Farquhar, C., 2007, Introduction and history of polycystic ovary syndrome. In: Kovacs G,Norman R, editors. Polycystic Ovary Syndrome. 2nd ed. Cambridge, UK: Cambridge University Press, 4–24. 

[13].  Bull, J.R., Rowland, S.P., Scherwitzl, E.B., Scherwitzl, R., Danielsson, K.G., Harper, J., 2019, Real-world menstrual cycle characteristics of more than 600,000 menstrual cycles. NPJ Digit Med, 2(1),83.

[14].  Rotterdam ESHRE/ASRM – 2004, Sponsored PCOS Consensus Workshop group. Revised 2003 consensus on diagnostic criteria and long term health risk related to poly cystic ovaries syndrome (PCOS). Hum Reprod, 19(1), 41 – 7.

[15].  Robert L. Rosenfield and David A. Ehrmann., 2016,The Pathogenesis of Polycystic Ovary Syndrome (PCOS): The Hypothesis of PCOS as Functional Ovarian Hyperandrogenism Revisited.Endocr Rev,  37(5),467–520.

[16].  Zephne, M., Van der spuy., Silke, J.D.,2004, The pathogenesis of infertility and early pregnancy loss in polycystic syndrome. Best Pract Res clin Obstetgynaecol,15 ( 5),755-71.

[17].  Rosenfield, R. L., 2015, The Diagnosis of Polycystic Ovary Syndrome in Adolescents Pediatri,136(6),1154-65. 

[18].  Nestler, J.E., 1997, Role of hyperinsulinemia in the pathogenesis of the polycystic ovary syndrome, and its clinical implications Semin. Reprod Endocrinol, 15(2),111-22. 

[19].  Rosenfield, R.L and Ehrmann, D.A., 2016, The Pathogenesis of Polycystic Ovary Syndrome (PCOS): The Hypothesis of PCOS as Functional Ovarian Hyperandrogenism Revisited. Endocr Rev, 37(5), 467–520.

[20].  Unluhizarci, K., Karaca, Z., Kelestimur, F., 2021, Role of insulin and insulin resistance in androgen excess disorders. World journal of diabetes, 12(5), 616.

[21].  Rouru, J., Anttila, L., Koskinen, P., Penttila, T.A., Irjala, K., Huupponen, R.,  Koulu, M. 1997, Serum leptin concentrations in women with polycystic ovary syndrome. J Clin Endocrinol Metab, 82(6), 1697-700.

[22].  Laughlin, G.A., Morales, A.J., Yen, S.S., 1997,Serum leptin levels in women with polycystic ovary syndrome: the role of insulin resistance/hyperinsulinemia. J Clin Endocrinol Metab, 82(6),1692-6.

[23].  Mulders, A.G., Laven, J.S., Eijkemans, M.J., de Jong, F.H., Themmen, A.P., Fauser, B.C., 2004,Changes in anti-Mullerian hormone serum concentrations over time suggest delayed ovarian ageing in normogonadotrophic anovulatory infertility. Hum Reprod, 19(9), 2036-42.

[24].  Wang, J. G., Nakhuda, G.S., Guarnaccia, M.M., Sauer, M.V., Lobo, R. A., 2007, Mullerian inhibiting substance and disrupted folliculogenesis in polycystic ovary syndrome. Am J Obstet Gynecol, 196(1), 77.

[25].  Durlinger, A.L., Kramer, P., Karels, B., de Jong, F.H., Uilenbroek, J.T., Grootegoed, J.A, Themmen, A.P., 1999,Control of primordial follicle recruitment by anti-Mullerian hormone in the mouse ovary. Endocrinology, 140(12),5789-96.

[26]. Piouka, A., Farmakiotis, D., Katsikis, I., Macut, D., Gerou, S., Panidis, D., 2009,Anti-Mullerian hormone levels reflect severity of PCOS but are negatively influenced by obesity: relationship with increased luteinizing hormone levels. Am physiol EndocrinolMetab, 296(2), E238-43.